Cameron Turtle is Chief Business Officer at Eidos Therapeutics, Inc. (EIDX). They have made 24 open-market trades across 2 companies since 2019, most recently 2026-10-01.
CIK 0001758363
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 24 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SYRE | SELL · 10b5-1 | 2026-10-01 | 2026-10-02 | $92.01 | $1.4M | -16.4% | — | — |
| SYRE | SELL · 10b5-1 | 2026-09-01 | 2026-09-03 | $87.29 | $1.3M | +4.6% | +6.2% | — |
| SYRE | SELL · 10b5-1 | 2026-08-03 | 2026-08-05 | $95.51 | $1.4M | +1.4% | -13.8% | — |
| SYRE | SELL · 10b5-1 | 2026-07-01 | 2026-07-02 | $87.69 | $1.3M | +17.3% | +9.5% | +2.5% |
| SYRE | SELL · 10b5-1 | 2026-06-01 | 2026-06-03 | $70.43 | $1.1M | +13.0% | +20.1% | +20.0% |
| SYRE | SELL · 10b5-1 | 2026-05-01 | 2026-05-01 | $71.37 | $1.1M | +11.8% | +3.2% | +48.6% |
| SYRE | SELL · 10b5-1 | 2026-04-01 | 2026-04-03 | $49.33 | $740K | +45.0% | +45.3% | +82.0% |
| SYRE | SELL · 10b5-1 | 2026-03-02 | 2026-03-03 | $42.19 | $633K | -0.6% | +18.5% | +75.5% |
| SYRE | SELL · 10b5-1 | 2026-02-02 | 2026-02-04 | $32.80 | $492K | +12.9% | +26.1% | +123.0% |
| SYRE | SELL · 10b5-1 | 2026-01-02 | 2026-01-06 | $30.68 | $460K | +9.2% | +8.2% | +60.9% |
| SYRE | SELL · 10b5-1 | 2025-12-01 | 2025-12-03 | $29.02 | $871K | +3.6% | -5.0% | +24.5% |
| SYRE | SELL · 10b5-1 | 2025-11-03 | 2025-11-05 | $23.33 | $2.1M | +8.1% | +48.5% | +47.8% |
| BBIO | SELL | 2020-12-28 | 2020-12-29 | $69.60 | $2.7M | +0.3% | -17.6% | -16.5% |
| EIDX | SELL | 2020-12-15 | 2020-12-16 | $111.85 | $5.0M | +10.0% | +11.7% | N/A |
| BBIO | SELL | 2020-11-24 | 2020-11-25 | $47.03 | $235K | +15.7% | +41.9% | +34.7% |
| EIDX | SELL | 2020-11-11 | 2020-11-13 | $74.52 | $2.0M | +10.1% | +40.8% | N/A |
| BBIO | SELL | 2020-11-05 | 2020-11-09 | $42.05 | $105K | +7.1% | +39.4% | +77.3% |
| EIDX | SELL | 2020-11-02 | 2020-11-03 | $70.70 | $1.8M | +9.5% | +27.5% | N/A |
| BBIO | SELL | 2020-09-30 | 2020-10-02 | $37.68 | $1.1M | +4.7% | +5.1% | +93.8% |
| BBIO | SELL | 2020-09-18 | 2020-09-22 | $42.01 | $105K | -1.0% | +0.4% | +64.5% |
| BBIO | SELL | 2020-09-15 | 2020-09-16 | $37.06 | $93K | -0.4% | +10.7% | +64.8% |
| BBIO | SELL | 2020-09-11 | 2020-09-15 | $35.02 | $70K | -1.6% | +5.2% | +64.2% |
| EIDX | SELL | 2020-09-10 | 2020-09-11 | $47.00 | $118K | -8.2% | +55.9% | +122.0% |
| EIDX | SELL | 2020-08-03 | 2020-08-05 | $39.75 | $509K | +1.2% | -1.0% | +76.5% |
| BBIO | SELL | 2020-06-30 | 2020-07-02 | $32.67 | $327K | +1.9% | -9.2% | +25.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.